Avoid common mistakes on your manuscript.
Correction to: International Journal of Clinical Oncology (2022) 27:1828–1838 https://doi.org/10.1007/s10147-022-02232-7
In the original publication, under section: Secondary end points, the sentence starting with: “KM estimated…” should read as:
KM estimated median DoR was not reached (95% CI 13.9–not reached) in patients who had confirmed responses.
In Results section, under heading Secondary end points, the sentence starting with: "Among..." should read as: Among the 31 patients with confirmed response by IRC, median time to response was 1.8 months (range, 0.95–12.9). In Table 2 the value of the entry: Duration of response, months, median (range) has been updated. The revised Table 2 is given in this Correction.
The original publication has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original publication has been revised due to text correction and revisions in Table 2.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Sugawara, S., Kondo, M., Yokoyama, T. et al. Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study. Int J Clin Oncol 28, 724–725 (2023). https://doi.org/10.1007/s10147-022-02286-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-022-02286-7